Introduction {#sec1-1}
============

Rheumatoid arthritis (RA) is the most common disease of the joints affecting about 1% of the world population.\[[@ref1]\] It involves not only the joints, but also all body systems such as the eyes, the respiratory system, and the heart. If left untreated, RA may develop into a crippling disease the treatment of which imposes heavy costs on the community and it might affect the economy of the society and its treatment and recovery also would annually impose great costs on the government.\[[@ref2]\] Significant advancements have been made for treatment of this disease during the recent years that is majorly consisted of simultaneous use of old and new disease-modifying drugs. The common treatment of RA is the triple method that involves administration of hydroxychloroquine, methotrexate, and prednisolone.\[[@ref3][@ref4]\] Disease-modifying anti-rheumatoid drugs (DMARDs) are drugs that would prevent joint destruction. There are many kinds of drugs that all would act through suppression of the immune system. DMARD\'s contains hydroxychloroquine (HCQ), methotrexate (MTX), leflunomide, and sulfasalazine (SSZ). Biologic drugs are in fact a type of DMARDs that would block the production of cytokines and wasfirst used for the treatment of RA in 1998.\[[@ref5]\] If the RA is not severe, one type of DMARDs would be used atfirst for the treatment. If significant improvement is not occurred, the dosage of the drug would be increased to full-dose or another drug from the same category would be combined with it and the patient would be monitored after 3 months. If the aim of the treatment, which is to resolve tenderness and swelling in the joint, is not achieved yet, biologic drugs would be added to the treatment. To determine the intensity of the disease, Disease Activity Score (DAS-28) was used. In this scale, the elements of the number inflamed joints, the number of swollen joints, erythrocyte sedimentation rate (ESR), and pain intensity rate in clinical examination (physical assessment) are used. Some studies report the use of biological DMARDs.\[[@ref6][@ref7]\] This study investigated the effect of DMARDs along with biologic drugs in the early stages of this disorder to show that the integrated use of these two drug categories may hasten the recovery of RA.

Materials and Methods {#sec1-2}
=====================

This nonrandomized clinical trial was conducted on the secondary data obtained from filed records of patients presenting to Rheumatology Clinic of Alzahra Hospital in Isfahan, Iran, in 2017. The diagnosis of RA was established by a rheumatologist and patients enrolled the study if they fulfilled the criteria on the basis of the American College of Rheumatology 2010 (ACR). The sample size was determined as 110 patients by a statistician with 95% confidence interval and error index of 0.05%. All the patients were under the baseline combination therapy (7.5 mg of MTX/week, 200 mg of HCQ/week, and 15 mg of prednisone/day and they were adjusted in sex, age, body mass index, and treatment duration. They were divided into two groups of 55 named Group A and Group B. Group A received prednisolone 15 mg/day along with one or two drugs of the DMARDs drugs (MTX and HCQ) for the treatment of RA. Group B received the drugs of Group A plus one biological drug (Subcutaneous Adalimumab 40 mg, per 2 weeks). The DMARDs include hydroxychloroquine, methotrexate, sulfasalazine, and leflunomide. The biological drugs include infliximab, adalimumab, and etanercept. In this study, parameters including age, gender, prednisolone dose, ESR, and C-reactive protein (CRP) were measured and recorded before and after pharmaceutical intervention and compared. Moreover, the two variables of physical assessment and global assessment were assessed and recorded before and after intervention and compared. Patients Global Assessment was ranged from 0 to 100 mm, although it was reported from 0 to 10 cm. Higher scores represent a higher level of disease activity or a worse global health. The proposed definition of "low global assessment" is ≤2.0 (scale 0--10). DAS-28 criteria were used to compare RA activity. The patients were divided into three groups on the basis of this scale:

Low disease activity with DAS-28 = 2.6--3.2Moderate disease activity with DAS-28 = 3.30--5.10High disease activity with DAS-28 \>5.01.

The data were analyzed with SPSS (Chicago: SPSS Inc. IBM Corp.) using descriptive statistics including frequency, standard deviation, and mean. *T*-test and analysis of covariance were used to compare the data between the two groups (*P* \< 0.05).

Results {#sec1-3}
=======

The mean age was 52.6 ± 11.9 years in Group A and 49.3 ± 11.9 years in Group B. Group A included 15 (27.3%) men and 40 (72.7%) women.

The ESR and CRP values and 100 mg Prednisolone dose before and after intervention are presented in [Table 1](#T1){ref-type="table"}. Physical assessment, global assessment, and DAS-28 values are shown in [Table 2](#T2){ref-type="table"}. [Table 3](#T3){ref-type="table"} compares global assessment, physical assessment, and DAS-28 before and after intervention between the two groups. The *P* value was adjusted for age, gender, and duration of treatment. As it can be observed in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, ESR was statistically significant between the two groups before intervention (*P* = 0.03); yet, the difference was not significant after intervention (*P* = 0.4). This is also true with CRP (before intervention, *P* = 0.01 and after intervention, *P* = 0.1). In addition, prednisolone dose was not significantly different between the two groups before and after intervention (before intervention, *P* = 1; after intervention, *P* = 0.8); however, global assessment and physical assessment was significantly different between the two groups before and after intervention (physical assessment, before intervention, *P* = 0.01, after intervention, *P* ≤ 0.001; global assessment, before intervention, *P* ≤ 0.001, after intervention, *P* ≤ 0.001). DAS-28 was significantly different between the two groups before intervention (*P* = 0.05); yet, the difference was not significant after intervention (*P* = 0.1).

###### 

Demographic information of the groups

  Variable                                                      A           B            Crude *P*               
  ------------------------------------------------------------- ----------- ------------ ----------- ----------- -------
  Gender                                                                                                         
   Male                                                         15 (27.3)                9 (16.4)                0.166
   Female                                                       40 (72.7)                46 (83.6)               
  Age (year)                                                                52.6±13.2                49.3±11.9   0.175
  Duration of treatment (year)                                              14.9±7.01                17.4±7.66   0.063
  CRP~0~ (beginning of the study)                                                                                
   -                                                            34 (66.7)                22 (40)                 0.012
   +1                                                           5 (9.9)                  15 (27.3)               
   +2                                                           10 (19.6)                10 (18.2)               
   +3                                                           2 (319)                  8 (14.5)                
  CRP~1~ (end of the study)                                                                                      
   -                                                            44 (86.3)                39 (70.9)               0.158
   +                                                            6 (11.8)                 14 (25.5)               
   +2                                                           1 (2)                    2 (3.6)                 
  *P* vlaue for CRP (within group)                              \<0.05                   \<0.05                  
  The dose of prednisolone at the beginning of the study (mg)               8.7±4.05                 8.7±2.58    0.1
  The dose of prednisolone at the end of the study (mg)                     5.3±2.85                 5.2±1.91    0.804
  ESR~0~ (beginning of the study) (mm/h)                                    33.01±22.2               41.7±20.9   0.037
  ESR~1~ (end of the study) (mm/h)                                          17.1±13.9                19.1±13.1   0.44
  *P* value for ESR (within groups)                                         \<0.05                   \<0.05      

ESR: Erythrocyte sedimentation rate, CRP: C-reactive protein, SD: Standard deviation

###### 

Compare results of disease activity score-28

  Variable                                       Mean±SD      Crude *P*    
  ---------------------------------------------- ------------ ------------ ---------
  Global assessment (beginning of the study)     50.8         40±11.5      \<0.001
  Global assessment (end of the study)           65.8±10.2    55.2±12.45   \<0.001
  Physical assessment (beginning of the study)   44.5±12.02   39.2±10.15   0.018
  Physical assessment (end of the study)         71.2±9.59    62±16.37     0.001
  DAS-28 (beginning of the study)                4.23±0.65    4.51±0.7     0.035
  DAS-28 (end of the study)                      3.52±0.79    3.75±85      0.117

Comparing the score of Global assessment and physical assessment between two groups. DAS: Disease activity score, SD: Standard deviation

###### 

Results of covariance analysis

  Variable                            Mean±SD     *P* (adjusted by age, gender, and duration of the disease)   
  ----------------------------------- ----------- ------------------------------------------------------------ -------
  Differ-ESR                          15.8±14.4   22.5±16.5                                                    0.008
  Differ~0~ P (physical assessment)   26.6±8.8    22.7±11.9                                                    0.979
  Differ~0~ G (global assessment)     15±6.1      15.2±7.4                                                     0.174
  Differ-DAS-28                       0.70±0.43   0.74±0.45                                                    0.8

ESR: Erythrocyte sedimentation rate, DAS: Disease activity score, SD: Standard deviation

Discussion {#sec1-4}
==========

DMARDs other than MTX include SSZ, HCQ, and leflunomide. These agents are listed in ACR guidelines and European league against rheumatism recommendations. However, little information has been obtained for other csDMARDs compared with MTX because most instances involve the addition of a biologic agent to existing DMARD therapy. Hence, studies investigating the efficacy of other csDMARDs for combination with a bDMARD are lacking.\[[@ref8]\]

In this study, the patients in Group A had a milder disease and received DMARDs. The moderate intensity and activity of the disease was DAS-28 = 4.23 (0.81). The patients in both groups were followed up for 3 months. The DAS-28 was 3.52 (0.79) for Group A after intervention which was statistically significant (*P* \< 0.001). Group B included patients with a more severe disease compared to Group A with DAS-28 = 4.51 (0.7). The patients in this group received Group A drugs plus biological medicines. Their DAS-28 increased to 3.75 (0.85) after 3 months at the end of intervention indicating a significant change (*P* \< 0.001); nonetheless, changes in Group B were greater than Group A using paired *t*-test. A study by Dewitt *et al*. compared the biological and nonbiological drugs in RA patients and found that biological drugs combined with Methotrexate exerted an effect similar to nonbiological drugs used as triple therapy.\[[@ref9]\] Another study carried out in the Netherlands compared the effect of biological drugs and DMARDs on RA patients for 2 years. The results indicated that recovery was faster in the group that received biological drugs plus Methotrexate.\[[@ref10]\] Another study was done on 10396 RA patients in Manchester University. The treatment began with biological medicines and continued with DMARDs.\[[@ref11]\] After 1 year, it was observed that recovery was very significant in these patients. Moreover, another study was performed on 632 RA patients in the Netherlands and compared the effect of etanercept and methotrexate. The findings suggested faster and greater healing of the patients who received etanercept.\[[@ref12]\] Our study demonstrated that DAS-28 criteria were not significantly different between the two groups after intervention meaning that although the patients who received biological drugs were those who had a more severe disease compared to Group A patients, the severity of their disease was not significantly different from Group A after intervention on the basis of DAS-28 criteria. This indicates greater and more effective recovery of the group that received DMARDs plus biological drugs simultaneously.

Conclusion {#sec1-5}
==========

It could be concluded from the results that simultaneous use of DMARDs and biologic drugs in RA patients could lead to better improvement of the disease symptoms and would decrease in the severity and activity of the disease.

Limitations {#sec2-1}
-----------

The limitation of the present study was the short period of intervention execution.

Recommendations {#sec2-2}
---------------

Although in the present study disease activity had a significant decrease following the used medicinal regimen, further studies are required to confirm this result.
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